Facebook
Twitter
LinkedIn
ForwardDiffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Outcomes of relapsed/refractory DLBCL differ based on the response to initial therapy, timing of relapse, and opportunity to undergo transplant. A multidisciplinary approach is required for appropriate patient selection and the management of acute toxicities to prevent fatal outcomes. There is a clear need to educate clinicians regarding the special considerations for the administration of CAR T-cell therapy and other targeted therapies in appropriately selected patients, the unique spectrum of treatment-related adverse events, and the effective management strategies. More importantly, clinicians should refer appropriate patients for participation in well-designed clinical studies to facilitate the development of novel treatment options.
Target Audience
This activity is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this program, participants should be able to:
- Describe the current treatment approach and the rationale for the development of novel treatment options for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Review the safety and efficacy of currently approved CAR T-cell therapies and other targeted therapies for relapsed/refractory DLBCL.
- Integrate targeted therapies into the overall treatment plan in appropriate patients with relapsed/refractory DLBCL.
Matthew J. Matasar, MD
Memorial Sloan Kettering Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
Presenting Faculty
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Matthew J. Matasar, MD
Bayer HealthCare: Consulting Fee; Grant/Research Support; Honoraria
Daiichi-Sankyo Co.: Consulting Fee
Genentech, Inc.: Consulting Fee; Grant/Research Support; Honoraria
GlaxoSmithKline: Grant/Research Support; Honoraria
IGM Biosciences: Grant/Research Support
Immunovaccine Technologies: Grant/Research Support; Honoraria
Janssen Phamaceutica Products, LP: Grant/Research Support; Honoraria
Juno Therapeutics, Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Equity Interest/Stock Options
Pharmacyclics: Grant/Research Support; Honoraria
Rocket Medical: Consulting Fee; Grant/Research Support
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support; Honoraria
Seattle Genetics, Inc.: Consulting Fee; Grant/Research Support; Honoraria
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Honoraria
Teva Pharmaceutical Industries Ltd: Consulting Fee
Moderator
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Consulting Fee
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support; Scientific Advisor
BMS/Celgene/Juno: Scientific Advisor
Celgene Corporation: Consulting Fee
Genentech, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-125-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until December 15, 2022. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing